Combination Therapy for Renal Cell Cancer: What Are Possible Options?

Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in p...

詳細記述

保存先:
書誌詳細
主要な著者: Santos, Napoleon, Wenger, Justin B., Havre, Pamela, Liu, Yanxia, Dagan, Roi, Imanirad, Iman, Ivey, Alison M., Zlotecki, Robert A., Algood, Chester B., Gilbert, Scott M., Allegra, Carmen J., Okunieff, Paul, Vieweg, Johannes, Dang, Nam H., Luesch, Hendrik, Dang, Long H.
フォーマット: Artigo
言語:Inglês
出版事項: S. Karger AG 2011
主題:
Review
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3225259/
https://ncbi.nlm.nih.gov/pubmed/22085914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000333470
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料